Scholarlink

Purpose <p>Pediatric lymphoma patients generally demonstrate a favorable long-term survival rate. The use of anti-programmed death-1 (PD-1) monoclonal antibodies has significantly improved the response rates in adult patients with refractory/relapsed lymphoma, particularly those with Hodgkin lymphoma and NK/T cell lymphoma. This study aimed to evaluate the real-world efficacy and safety of PD-1 antibody monotherapy or combination therapy in pediatric lymphoma patients.</p> Methods <p>From March 1, 2017, to October 25, 2022, we retrospectively analyzed data from 41 pediatric lymphoma patients who received PD-1 antibody treatment, including those with Hodgkin lymphoma, extranodal NK/T cell lymphoma, primary mediastinal large B-cell lymphoma, and other subtypes. Kaplan–Meier analysis was used to estimate progression-free survival (PFS) and overall survival (OS). Descriptive statistics were used to report response rates and adverse effects.</p> Results <p>The median follow-up period was 22.4&#xa0;months (range, 1.3–67.6&#xa0;months), and the overall response rate for the entire cohort was 82.9% (51.2% complete response [CR], 31.7% partial response [PR]). Only two patients died due to disease progression. The two-year PFS rate was 63.0 ± 8.5%, and the median OS and PFS were not reached. PD-1 antibodies were generally well tolerated, particularly in patients receiving monotherapy.</p> Conclusion <p>Our findings suggest that PD-1 antibody treatment offers a high response rate and low toxicity in pediatric lymphoma patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Real-world study of efficacy and safety of PD-1 antibody monotherapy and combination therapy in pediatric lymphoma patients

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月5日

查看全文
  • Yingxia Lan,
  • Zizheng Xiao,
  • Yi Que,
  • Yi Wang,
  • Ye Hong,
  • Juan Wang,
  • Suying Lu,
  • Junting Huang,
  • Feifei Sun,
  • Zijun Zhen,
  • Juan Liu,
  • Jiaqian Xu,
  • Yanpeng Wu,
  • Lanying Guo,
  • M. James You,
  • Jia Zhu,
  • Yizhuo Zhang

摘要

Purpose

Pediatric lymphoma patients generally demonstrate a favorable long-term survival rate. The use of anti-programmed death-1 (PD-1) monoclonal antibodies has significantly improved the response rates in adult patients with refractory/relapsed lymphoma, particularly those with Hodgkin lymphoma and NK/T cell lymphoma. This study aimed to evaluate the real-world efficacy and safety of PD-1 antibody monotherapy or combination therapy in pediatric lymphoma patients.

Methods

From March 1, 2017, to October 25, 2022, we retrospectively analyzed data from 41 pediatric lymphoma patients who received PD-1 antibody treatment, including those with Hodgkin lymphoma, extranodal NK/T cell lymphoma, primary mediastinal large B-cell lymphoma, and other subtypes. Kaplan–Meier analysis was used to estimate progression-free survival (PFS) and overall survival (OS). Descriptive statistics were used to report response rates and adverse effects.

Results

The median follow-up period was 22.4 months (range, 1.3–67.6 months), and the overall response rate for the entire cohort was 82.9% (51.2% complete response [CR], 31.7% partial response [PR]). Only two patients died due to disease progression. The two-year PFS rate was 63.0 ± 8.5%, and the median OS and PFS were not reached. PD-1 antibodies were generally well tolerated, particularly in patients receiving monotherapy.

Conclusion

Our findings suggest that PD-1 antibody treatment offers a high response rate and low toxicity in pediatric lymphoma patients.